Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jimaixin dosing-frequency trial for chemotherapy-induced anemia in non-bone marrow malignancies
ChiCTR1900024947Phase 4Recruiting
- Sponsor
- Anyang Cancer Hospital
- Start
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of epoetin alfa in chemotherapy-induced anaemia (CIA) and anaemia (2 arms), sponsored by Anyang Cancer Hospital. Primary endpoint: Hemoglobin. Started Aug 2019; status: recruiting.
02
Drugs
epoetin alfa
03
Conditions
chemotherapy-induced anaemia (CIA)anaemia
Beyond the preview
Go deeper on ChiCTR1900024947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024947.